227 related articles for article (PubMed ID: 2898536)
1. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group.
J Natl Cancer Inst; 1988 Jul; 80(10):751-5. PubMed ID: 2898536
[TBL] [Abstract][Full Text] [Related]
2. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study.
Klaassen DJ; MacIntyre JM; Catton GE; Engstrom PF; Moertel CG
J Clin Oncol; 1985 Mar; 3(3):373-8. PubMed ID: 3973648
[TBL] [Abstract][Full Text] [Related]
3. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Moertel CG; Frytak S; Hahn RG; O'Connell MJ; Reitemeier RJ; Rubin J; Schutt AJ; Weiland LH; Childs DS; Holbrook MA; Lavin PT; Livstone E; Spiro H; Knowlton A; Kalser M; Barkin J; Lessner H; Mann-Kaplan R; Ramming K; Douglas HO; Thomas P; Nave H; Bateman J; Lokich J; Brooks J; Chaffey J; Corson JM; Zamcheck N; Novak JW
Cancer; 1981 Oct; 48(8):1705-10. PubMed ID: 7284971
[TBL] [Abstract][Full Text] [Related]
4. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial.
Hazel JJ; Thirlwell MP; Huggins M; Maksymiuk A; MacFarlane JK
J Can Assoc Radiol; 1981 Sep; 32(3):164-5. PubMed ID: 7028759
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Kalser MH; Ellenberg SS
Arch Surg; 1985 Aug; 120(8):899-903. PubMed ID: 4015380
[TBL] [Abstract][Full Text] [Related]
6. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris HA; Moore MJ; Andersen J; Green MR; Rothenberg ML; Modiano MR; Cripps MC; Portenoy RK; Storniolo AM; Tarassoff P; Nelson R; Dorr FA; Stephens CD; Von Hoff DD
J Clin Oncol; 1997 Jun; 15(6):2403-13. PubMed ID: 9196156
[TBL] [Abstract][Full Text] [Related]
7. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group.
Cancer; 1987 Jun; 59(12):2006-10. PubMed ID: 3567862
[TBL] [Abstract][Full Text] [Related]
8. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.
Gaspar L; Scott C; Rotman M; Asbell S; Phillips T; Wasserman T; McKenna WG; Byhardt R
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(4):745-51. PubMed ID: 9128946
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer.
Zhong J; Switchenko J; Behera M; Kooby D; Maithel SK; McDonald MW; Lin JY; Cassidy RJ; El-Rayes B; Landry J; Patel PR
Ann Surg Oncol; 2018 Apr; 25(4):1026-1033. PubMed ID: 29327180
[TBL] [Abstract][Full Text] [Related]
10. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer.
Mahadevan A; Moningi S; Grimm J; Li XA; Forster KM; Palta M; Prior P; Goodman KA; Narang A; Heron DE; Lo SS; Urbanic J; Herman JM
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):206-216. PubMed ID: 33358561
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
[TBL] [Abstract][Full Text] [Related]
12. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Conroy T; Hammel P; Hebbar M; Ben Abdelghani M; Wei AC; Raoul JL; Choné L; Francois E; Artru P; Biagi JJ; Lecomte T; Assenat E; Faroux R; Ychou M; Volet J; Sauvanet A; Breysacher G; Di Fiore F; Cripps C; Kavan P; Texereau P; Bouhier-Leporrier K; Khemissa-Akouz F; Legoux JL; Juzyna B; Gourgou S; O'Callaghan CJ; Jouffroy-Zeller C; Rat P; Malka D; Castan F; Bachet JB;
N Engl J Med; 2018 Dec; 379(25):2395-2406. PubMed ID: 30575490
[TBL] [Abstract][Full Text] [Related]
13. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Versteijne E; Suker M; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Eijck CH; van Tienhoven G;
J Clin Oncol; 2020 Jun; 38(16):1763-1773. PubMed ID: 32105518
[TBL] [Abstract][Full Text] [Related]
14. Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial.
Abrams RA; Winter KA; Safran H; Goodman KA; Regine WF; Berger AC; Gillin MT; Philip PA; Lowy AM; Wu A; DiPetrillo TA; Corn BW; Seaward SA; Haddock MG; Song S; Jiang Y; Fisher BJ; Katz AW; Mehta S; Willett CG; Crane CH
Am J Clin Oncol; 2020 Mar; 43(3):173-179. PubMed ID: 31985516
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma-A Critical Review of Randomised Trials.
Ejlsmark MW; Schytte T; Bernchou U; Bahij R; Weber B; Mortensen MB; Pfeiffer P
Curr Oncol; 2023 Jul; 30(7):6820-6837. PubMed ID: 37504359
[TBL] [Abstract][Full Text] [Related]
16. Proton Therapy for Unresectable and Medically Inoperable Locally Advanced Pancreatic Cancer: Results From a Multi-Institutional Prospective Registry.
Eckstein J; Choi JI; Lozano A; Ohri N; Press R; Hasan S; Kabarriti R; Chang J; Urbanic J; Durci M; Mohammed N; Stevens C; Tsai H; Apisarnthanarax S; Regine W; Vargas C; Nichols R; Herman J; Simone CB; Chhabra A
Adv Radiat Oncol; 2023; 8(5):101250. PubMed ID: 37408677
[TBL] [Abstract][Full Text] [Related]
17. Survival Outcomes and Failure Patterns in Patients with Inoperable Non-Metastatic Pancreatic Cancer Treated with Definitive Radiotherapy.
Cao B; Zhang L; Wu C; Liu X; Wang Q; Tong F; Yang W; Wang J
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190142
[TBL] [Abstract][Full Text] [Related]
18. Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis.
Wang ZM; Ma HB; Meng Y
BMC Gastroenterol; 2023 Apr; 23(1):107. PubMed ID: 37020202
[TBL] [Abstract][Full Text] [Related]
19. Evolution of Radiation Therapy in Pancreas Cancer Management toward MRI-Guided Adaptive Radiation Therapy.
Yalamanchili A; Thomas TO; Dajani S; Hayes JP
J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36143027
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer.
Sanghvi SM; Coffman AR; Hsueh CT; Kang J; Park A; Solomon NL; Garberoglio CA; Reeves ME; Slater JD; Yang GY
J Gastrointest Oncol; 2022 Aug; 13(4):1989-1996. PubMed ID: 36092320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
